rosuvastatin

Brand: Crestor

⚠ BBW Prototype: atorvastatin
Drug Class: statin
Drug Family: antilipemic
Subclass: HMG-CoA reductase inhibitor (synthetic)
Organ Systems: cardiovascular

Mechanism of Action

Potent synthetic statin; less CYP3A4 metabolism than atorvastatin; most hydrophilic statin; high LDL reduction efficacy (up to 63% at maximum dose).

HMG-CoA reductase

Indications

  • hyperlipidemia
  • ASCVD prevention
  • familial hypercholesterolemia
  • mixed dyslipidemia

Contraindications

  • active liver disease
  • pregnancy
  • unexplained transaminase elevation
  • renal impairment (reduce dose)

Adverse Effects

Common

  • myalgia
  • headache
  • nausea
  • hyperglycemia

Serious

  • rhabdomyolysis
  • myopathy
  • new-onset diabetes

Pharmacokinetics (ADME)

Absorption 20% oral bioavailability
Distribution moderate
Metabolism CYP2C9 minor; largely unchanged
Excretion fecal 90%
Half-life 19 hours
Onset 2-4 hours
Peak 3-5 hours
Duration 24 hours
Protein Binding 88%
Vd 134 L

Drug Interactions

Drug / Agent Mechanism Severity
cyclosporine markedly increases rosuvastatin — cap at 5 mg major
gemfibrozil OATP1B1 inhibition; cap at 10 mg major
anticoagulants (warfarin) may increase INR moderate

Nursing Considerations

  1. Most potent LDL-lowering statin per mg
  2. JUPITER trial: reduced CV events in patients with normal LDL but elevated hsCRP
  3. Dose cap with cyclosporine (5 mg) and gemfibrozil (10 mg)
  4. Asian patients may have higher plasma levels — start at lower doses (5 mg)

Clinical Pearls

  • JUPITER trial: rosuvastatin 20 mg reduced CV events in primary prevention with elevated hsCRP
  • Most hydrophilic statin — theoretically reduced risk of muscle/CNS side effects vs lipophilic agents (not proven)

Safety Profile

Pregnancy contraindicated
Lactation contraindicated
Renal Adjustment Required
Hepatic Adjustment Required
TDM Not required
Guideline Update pending

Concordance Terms

Cross-referenced clinical concepts — click any term to see all content where it appears.